BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Wedbush Starts ProNAi Therapeutics (DNAI) at Outperform
August 10, 2015 7:34 AM EDTWedbush initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten commented, "DNAI is a clinical-stage biotech company developing a novel therapeutic platform based on DNA interference (DNAi). ProNAi's lead candidate, PNT2258, is a... More
Jefferies Starts ProNAi Therapeutics (DNAI) at Buy
August 10, 2015 7:04 AM EDTJefferies initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $37.00.
Analyst Brian Abrahams commented, "ProNAi is developing PNT2258, a Bcl2-directed oligonucleotide, in ph.II for hematological cancers. We believe DNAI is undervalued based on 2258s... More
